Clinical Research Directory

Inclusion Criteria: 1. 18-85 years old. 2. Hospitalized participants in ICU who did not receive Ceftazidime Avibactam treatment within 15 days before joining the study. 3. Participants with severe infection (refer to the 2022 sepsis3.0 guidelines for the definition of severe infection). 4. at least one carbapenem-resistant Gram-negative pathogen (including but not limited to carbapenem-resistant Enterobacteriaceae and / or Pseudomonas aeruginosa) was confirmed by bacterial culture in the primary infection site samples. 5. sufficient respiratory secretions, blood and peritoneal effusion can be obtained within 48 hours before the first administration for bacterial culture and drug sensitivity test. 6. intravenous injection of Ceftazidime Avibactam for more than 72 hours. 7. understand compliance with research procedures and methods, voluntarily participate in this study, and sign informed consent in writing. Exclusion Criteria: 1. Participants are less than 18. 2. Death within 72 hours after the start of treatment. 3. Known resistance to β-lactam antibacterial drugs including cephalosporins, cephalosporin compound preparations containing β-lactamase inhibitors, or Those with a history of allergies to ceftazidime avibactam sodium for injection and its excipients. 4. No indication for treatment with ceftazidime avibactam. 5. Pregnant and lactating women.